Drug Trial Radar · NCT06873763
Nelmastobart in Combination With Trifluridine/ Tipiracil and Bevacizumab in Metastatic/ Recurrent Colorectal Cancer
Last checked: Nov 20, 2026Latest source record: Jul 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
52
Planned (sponsor's estimate)
Start
Jun 9, 2025
Primary completion
Dec 2025
Study completion Mar 2027
Sponsor
- Lead sponsor
- STCube, Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 13, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this multi-center, single-group, open-label Phase Ib/II study is to evaluate the safety, pharmacokinetics, and efficacy of nelmastobart in combination with trifluridine/tipiracil and bevacizumab in metastatic or recurrent colorectal cancer patients with resistance or intolerance to oxaliplatin- and irinotecan-based chemotherapy, and to determine the maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D), and the efficacy and safety of the combination therapy in BTN1A1-positive patients.
Conditions
- Metastatic Colorectal Cancer (CRC)
- Recurrent Colorectal Cancer
Interventions
Nelmastobart 800 mg+Trifluridine/Tipiracil+ BevacizumabDrug
Trifluridine/tipiracil is dose-deescalated from 35 mg/m² to 30 mg/m² and 25 mg/m² to determine the RP2D, in combination with fixed doses of Nelmastobart and Bevacizumab, in patients with metastatic colorectal cancer who are refractory or intolerant to prior oxaliplatin- and irinotecan-based chemotherapy.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of DLTTime frame: up to 6 months
- RP2D(Recommended Phase 2 Dose)Time frame: up to 2 years
- MTD(Maximum Tolerated Dose)Time frame: up to 2 years
- Progression Free Survival (PFS) rateTime frame: up to 2 years
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Korea University Anam Hospital
Seoul, South Korea · Recruiting
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, South Korea · Not yet recruiting
Seoul National University Hospital
Seoul, KR, South Korea · Not yet recruiting
Severance Hospital
Seoul, KR, South Korea · Not yet recruiting
Asan Medical Center
Seoul, KR, South Korea · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.